Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling.

CONCLUSIONS: This is the first study to report the expression of ROR2 in breast cancer. Breast cancer patients expressing ROR2 had a significantly worse prognosis than those lacking ROR2. ROR2 may regulate both β-catenin-dependent and β-catenin-independent Wnt signalling pathways, and represents a potential diagnostic and therapeutic target. PMID: 25209439 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25209439?dopt=Abstract

Source: Clinical Breast Cancer - September 11, 2014 Category: Cancer & Oncology Authors: Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE Tags: J Cancer Res Clin Oncol Source Type: research